3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Fulvestrant
34
Specimen Handling
31
Letrozole
30
Paclitaxel
23
pembrolizumab
19
Carboplatin
19
ribociclib
18
exemestane
18
Capecitabine
17
Trastuzumab
16
Tamoxifen
16
Magnetic Resonance Spectroscopy
16
palbociclib
15
Anastrozole
15
Biopsy
14
trastuzumab deruxtecan
13
abemaciclib
13
pertuzumab
11
Radiotherapy
11
Cyclophosphamide
9
inavolisib
8
elacestrant
8
olaparib
7
Taxes
7
Standard of Care
7
Radiation
7
Mastectomy, Segmental
7
Goserelin
7
130-nm albumin-bound paclitaxel
7
giredestrant
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Imlunestrant
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT07287098
2026-05-22
preEMBER
Eli Lilly and Company
Phase 2
Not yet recruiting
600 enrolled